Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.


Market Cap$6.72B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Halozyme Therapeutics Inc.Halozyme Therapeutics Inc.21.10%179%8.98.4

Target Price by Analysts

2.5% upsideHalozyme Therapeutics Target Price DetailsTarget Price

Current Fair Value

68.1% downside

Overvalued by 68.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$6.72 Billion
Enterprise Value$7.76 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$2.42
Outstanding Shares127,274,000
Avg 30 Day Volume1,413,743


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio21.09
Price to Sales8.86
Price to Book Ratio53.18
Enterprise Value to Revenue8.99
Enterprise Value to EBIT20.46
Enterprise Value to Net Income24
Total Debt to Enterprise0.19
Debt to Equity8.44

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Halozyme Therapeutics Inc.

CEO: Helen Torley